

## Supplemental Data S3

### Detailed statistical report of the intranasal SARS-CoV-2 inhibitory effects of COVITRAP™

VOCs	Product	Timepoint of nasal fluid sample collection in relation to the study product application	<i>n</i>	Median of % inhibition (IQR25%-IQR75%)	95% CI of median	Wilcoxon test (P value)
Ancestral	Placebo	Before	4	7.69 (1.34 - 67.38)	0 - 86.51	0.1875
		Immediately after	4	14.35 (3.25 - 75.39)	0 - 95.27	
	COVITRAP™	Before	13	12.41 (3.56 - 27.39)	0 - 33.63	1.2207E-4
		Immediately after	13	97.58 (97.11 - 97.67)	96.93 - 97.72	
	Placebo	Before	5	24.16 (6.48 - 94.45)	0 - 97.73	0.1563
		6 hours after	5	46.68 (33.58 - 86.97)	20.72 - 97.86	
	COVITRAP™	Before	14	24.03 (12.2 - 34.9)	4.06 - 38.36	6.1035E-05
		6 hours after	14	91.72 (76.2 - 97.04)	66.43 - 97.29	
Delta	Placebo	Before	4	2.98 (2.25 - 49.94)	2.13 - 65.46	0.3125
		Immediately after	4	5.38 (0.53 - 65.7)	0 - 84.73	
	COVITRAP™	Before	13	8.02 (1.35 - 30.07)	0.83 - 35.06	1.2207E-4
		Immediately after	13	97.44 (96.88 - 97.57)	96.61 - 97.62	
	Placebo	Before	5	35.01 (6.96 - 86.66)	0 - 96.83	0.0938
		6 hours after	5	48.4 (23.64 - 86.17)	23.08 - 97.63	
	COVITRAP™	Before	14	21.53 (3.979 - 23.23)	0 - 24.04	6.1035E-05
		6 hours after	14	88.67 (73.01 - 96.31)	70.83 - 96.92	
Omicron BA.2	Placebo	Before	4	2.16 (0 - 33.58)	0 - 43.33	0.1250
		Immediately after	4	12.5 (2.39 - 50.35)	0 - 61.98	
	COVITRAP™	Before	13	3.64 (0 - 10.99)	0 - 11.58	1.2207E-4
		Immediately after	13	94.65 (92.43 - 95.54)	91.69 - 95.74	
	Placebo	Before	5	13.63 (3.14 - 50.38)	0 - 70.69	0.0625
		6 hours after	5	17.77 (13.32 - 59.87)	10.35 - 81.63	
	COVITRAP™	Before	14	8.59 (0.09 - 15.79)	0.04 - 16.78	6.1035E-05
		6 hours after	14	70.6 (54.83 - 85.09)	48.33 - 88.95	